HCPLive Network

Hemophilia Reports

Latest Issue
Recombinant FVIII Fc Under Review in Europe
By Rachel Lutz
A recombinant FVIII Fc fusion protein product candidate for the treatment of hemophilia A is under review in Europe.
FDA Receives Submission for Hemophilia A Drug BAX 855
By Rachel Lutz
The US Food and Drug Administration recently announced it had received a submission for a biologics license application from Nektar Therapeutics and Baxter International Inc for an investigational, extended half-life recombinant factor VIII treatment for hemophilia A.
Hemophilia Cured in Mice Models Using New Genome Editing Method
By Rachel Lutz
Stanford researchers were able to cure hemophilia in mice models using a new genome editing method. Their findings were published in Nature.
Inhibitor Development Risk in Patients with Hemophilia Higher than Previously Thought
By Rachel Lutz
For mild hemophilia A patients, the risk of inhibitor development is higher than previously thought, according to findings published in the journal Blood.
Long-Term Relief for Hemophilia B Patients
By Rachel Lutz
Long-term relief for hemophilia B patients was achieved via adeno-associated virus treatments, according to findings published in The New England Journal of Medicine.
Modified Plant Cell Treatment Effective in Animal Models of Hemophilia A
By Rachel Lutz
In mice models of hemophilia A, a modified tobacco plant diet was effective at prohibiting the development of inhibitors, according to research published in the journal Blood.